"The Effects of Caffeine on Overactive Bladder Symptoms and Mental Health in Postmenopausal Women"

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

55 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-07-31

Study Completion Date

2018-09-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to observe effects of caffeine on overactive bladder symptoms and wellbeing. This study looks at whether caffeine has bad effects on urinary symptoms or if lower doses of caffeine decrease the effects.

The study will propose the following hypothesis:

1. The voiding and mental health symptoms will be greatest in the high dose treatment and lowest in the placebo treatment.
2. The low dose treatment will produce more voiding and mental health symptoms than the placebo treatment.
3. Voiding and mental health symptoms will be mediated by hydration status of the patient which will be assessed using a Tanita Scale.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Caffeine on Sleep-wake Regulation in Teenagers

NCT04321785

Adolescence Caffeine

COMPLETED NA

A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age

NCT07082829

Excessive Daytime Sleepiness

RECRUITING PHASE1

Risk and Benefit Assessment of Hypnotic Agents for Sleep Disorders Among Elderly

NCT02648776

Sleep Disorders

UNKNOWN

Efficacy Study of EVT 201 in the Treatment of Elderly Patients With Daytime Sleepiness

NCT00401284

Sleep Initiation and Maintenance Disorders

COMPLETED PHASE2

Acute Effects of Gabapentin in Sleep Parameters and Hormonal Release During Sleep in Older Men

NCT02599701

Sleep

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects will be exposed to 200 mg and 400 mg caffeine pills and placebo pills (free of caffeine). During each treatment period, participants will be required to avoid caffeine (except for the caffeine within the given treatment). The study is staged into 3 phases, which will last for 7 days each. After enrollment, participants will be asked to refrain from consuming any substances containing caffeine during the 21 days of treatment. Instead of coffee or other caffeine items, they will be exposed to caffeine in pill form. Participants will complete each treatment in a random, cross over blinded fashion. One phase of treatment will have participants consume two 200 mg-caffeine pills a day (total of 400 mg of caffeine/day), a second treatment will have participants consume one 200 mg-caffeine pill and one placebo pill a day. And the final treatment will have participants consume two placebo pills each day. Treatment phases will be assigned randomly to each participant. The participant will not know which phase they are receiving.

Prior to the treatment, the participant will be asked to fill out a detailed diet log of her eating and drinking habits. Participants will also be asked a series of questions on a survey related to bladder symptoms and mental health periodically throughout the study. It will take about 30 minutes of their time to answer the questionnaires at individual time points.

During the 21 days of the study period participants will be asked to self-monitor fluid intake and note any major changes of fluid intake compared to the initial intake log. They will be asked to conduct a 24-hour voiding and defecation log at two different time points within each treatment phase as well as prior to the study. 24-hour urine will be collected during each treatment phase at two different time points as well as prior to the study. Participants weight and lean body mass will be assessed in clinic using a Tanita scale at two times within each treatment phase and one time prior to the study

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overactive Bladder Caffeine Menopause

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

400 mg of caffeine/day (Two 200mg pills/day)

One phase of treatment will have participants consume two 200 mg-caffeine pills day (total of 400 mg of caffeine/ d) for 7 days.

Group Type ACTIVE_COMPARATOR